Format

Send to

Choose Destination
See comment in PubMed Commons below

Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate.

Abstract

Clinical trials administering supplemental ascorbate to terminal cancer patients were conducted at two hospitals in Japan. During the period 1973-1977 there were 99 patients with terminal cancer at the Fukuoka Torikai Hospital. The average times of survival after the date of designation as terminal were 43 days for 44 low-ascorbate patients and 246 days for 55 high-ascorbate patients. Three of the high-ascorbate patients were still alive, their average survival being 1550 days, on April 1, 1980. Similar effectiveness of ascorbate was also observed at the Kamioka Kozan Hospital. There were 31 patients with terminal cancer during the period 1975-1979. The average survival times were 48 days for 19 control patients and 115 days for 6 high-ascorbate patients. One of the high-ascorbate patients was still alive, his survival being 215 days. In addition to the increase in survival times, the administration of large doses of ascorbate seemed to improve the quality of life.

PMID:
6811475
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center